Canton, MI. (September 14, 2009) – MMS Holdings Inc., announces a strategic alliance with BioClinica, a leading global provider of clinical trials services, to offer Phase 1-4 EDC services. These services are complimentary to MMS and will be co-marketed with their statistical, programming, and medical writing services. This will allow pharmaceutical companies an option to have their reports and submissions as quickly as possible with proven quality. The alliance between MMS Holdings and BioClinica allows both companies to offer more streamlined solutions to pharmaceutical companies with quality as the key driver.
About MMS Holdings Inc.
MMS Holdings Inc. is based in Canton, MI and is a highly experienced pharmaceutical service organization that is focused on quality deliverables in the areas of Clinical Programming, Biostatistics, Medical /Regulatory Writing and Comprehensive Pharmacovigilance. Commitment to Quality deliverables with robust submission experience sets MMS apart from traditional service providers. MMS Holdings Inc. is ISO-9001 certified for all services and maintains detailed quality metrics for every project. For more information visit: www.mmsholdings.com
About BioClinica
BioClinica, Inc. is a leading global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process. BioClinica offers industry-leading medical image management and best-of-breed electronic data capture to companies in the life sciences industry. In addition, BioClinica offers solutions that combine these core services to maximize efficiency and manageability throughout the entire clinical development process. With more than 2,000 successful trials, BioClinica is unsurpassed in its knowledge and experience, helping bring many of today’s drugs from early phase development through final approval. BioClinica operates two state-of-the-art, FDA-compliant core labs in the United States and Europe, with business offices in the United States, France, Germany, the United Kingdom and the Netherlands. For more information visit: www.bioclinica.com
